 Remamazalam is a novel ultra short acting benzodiazepine with a unique pharmacological profile that includes rapid onset and offset of sedation and a predictable duration of action. It is also characterized by relatively high clearance, small steady state volume of distribution, short elimination half-life, short context sensitive half-life, and fast onset and recovery, indicating rapid elimination, minimal tissue accumulation, and good control. Remamazalam possesses a superior safety profile, including low liability for cardiorespiratory depression and injection pain, making it a preferred hypnotic agent in various clinical settings. However, further studies regarding its recovery issues or postoperative complications, characteristics of electroencephalogram changes, and cost-benefit analyses are required to facilitate its widespread use. This article was authored by Ken Mee Kim.